ClinicalTrials.gg
RecruitingNCT05422859MobiDigUpdated Jul 5, 2024

Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg

An interventional study of MobiDig in Heart Failure, sponsored by German Heart Institute. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by German Heart Institute · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by German Heart Institute — 3 open to participants now, 4 under way, none of them phase 3. Heart Failure · German Heart Institute.

Started
2022
with 1 other
No phase
4 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Heart Failure by German Heart Institute, this one is one of 2 that started in 2022, is one of 4 with no phase, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 11 studies in Heart Failure by German Heart Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by German Heart Institute, or all of them as a file.
02

Study summary

The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive/rehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg.

The aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of heart failure
  • Treatment in a certified Heart Failure Unit center in Berlin or Brandenburg
  • Written of the participants
  • User of a mobile device with an iOS operating system

Exclusion criteria

Exclusion Criteria:

  • Addiction or other illnesses that do not allow the participants to assess the nature and scope as well as possible consequences of participation or its scientific evaluation
  • insufficient knowledge of the German language, which is necessary to use the application
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    MobiDig

    50 patients will have access to a mobile phone application for 3 months.

    Other: MobiDig

Interventions

  • OtherMobiDig

    The application will contain the following modules: 1. information and knowledge about heart failure; 2. vital sign diary, which can be sent to the certified HFU 3. pedometer (individualized step-goal), cardiac home training videos 4. "frequently asked questions" and connection to a certified HFU provider by a heart failure hotline

06

What researchers measure

Primary outcomes

  1. Acceptance of the application

    The acceptence of the application will be measured by the User Experience Questionnaire. It consists of 9 items that can be rated on a 7-point Likert scale. -3 (fully agree with negative term) to +3 (fully agree with positive term). A higher total score means a better outcome.

    Time frame: 3 months

  2. Change in quality of life

    Quality of life measured by Kansas City Cardiomyopathy Questionnaire using the validated 12-item version which has been described by Spertus et Jones (doi: 10.1161/CIRCOUTCOMES.115.001958.) A higher score means a better outcome.

    Time frame: Baseline and 3 months

  3. Patient reported outcomes

    Health-related quality of life will be measured by the "Patient Related Outcome and Measurement Information System" (PROMIS) test. Including 23 items that will be analyzed via Likert scale 1 (impossible/never) to 5 (no limitations/very good). A higher score means a better outcome.

    Time frame: Baseline and 3 months

  4. Change in symptoms of heart failure

    Symptoms of heart failure will be assessed by the New York Heart Association functional class. Consisting of four classes (I-IV), the higher, the worse the outcome.

    Time frame: Baseline and 3 months

  5. Change in six-minute walk distance

    Functional capacity will be assessed by the 6-minute walk test

    Time frame: Baseline and 3 months

  6. Change in daily walking distances

    Functional capacity will be assessed by the steps taken within 24 hours (pedometry).

    Time frame: Baseline and 3 months

  7. Change in heart failure biomarker

    Heart failure severity will be assessed by the biomarker NT-proBNP.

    Time frame: Baseline and 3 months

  8. Number of hospitalizations

    Number of hospitalizations for heart failure will be assessed.

    Time frame: 3 months

  9. Length of hospitalizations

    Length of in-hospital stay of hospitalizations for heart failure will be assessed.

    Time frame: 3 months

07

Study locations

2 of 3 sites recruiting
  • Deutsches Herzzentrum der Charité - Universitätsmedizin Berlin
    Berlin, Deutschland 13353, Germany
    Recruiting
  • Charité - Universitätsmedizin Berlin: Campus Virchow-Klinikum
    Berlin, 13353, Germany
    Recruiting
    • Frank Edelmann, Prof. Dr. · Contact
  • Herzzentrum Berlin
    Bernau, Germany
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2025, 30 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 30 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 21, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2025
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05422859
Lead sponsor
German Heart Institute
Collaborators
Federal Ministry of Health, Germany
Responsible party
Sabine Huebler (Head of Studienzentrale, German Heart Institute) — Principal investigator
First posted
Jun 21, 2022
Start date
Jul 1, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Jul 5, 2024

Study contacts

Isabell A Just, Dr.
Contact
ijust@dhzb.de
00493045932025
Felix Schoenrath, Prof. Dr.
Contact
schoenrath@dhzb.de
00493045932085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion